Lantern Pharma (NASDAQ: LTRN) announced the expansion of its predictBBB platform into a Large Quantitative Model (LQM), delivering a real-time, web-based molecular intelligence engine. This enhanced platform enables researchers to generate comprehensive developability profiles for small molecules from a single SMILES input, leveraging Lantern’s RADR AI technology. The LQM provides rapid, high-dimensional analysis across physicochemical properties, drug-likeness, structural architecture, and topological mapping, with benchmark-validated performance designed to streamline drug discovery workflows and broaden access to advanced computational tools.
The expanded platform represents a significant advancement in computational drug discovery. By integrating machine learning and AI, the LQM can process vast amounts of molecular data, offering insights that were previously time-consuming or impossible to obtain. Researchers can now evaluate potential drug candidates more efficiently, reducing the time and cost associated with early-stage development. The platform’s accessibility via a web-based interface means that scientists worldwide can utilize these powerful tools without needing specialized hardware or software.
Lantern Pharma is a clinical-stage precision oncology company that leverages AI, machine learning, and its proprietary RADR platform to transform the development of cancer therapies. The company’s clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary.
Additionally, Lantern’s withZeta.ai, a multi-agentic AI co-scientist platform, is now commercially available as a subscription-based research platform for the global biomedical and drug development community, representing a new revenue stream for the company. Lantern operates an AI Center of Excellence in Bengaluru, India and is headquartered in Dallas, Texas.
For more details on the predictBBB platform expansion, visit https://ibn.fm/XqWld. For the latest news and updates on Lantern Pharma, visit https://ibn.fm/LTRN.
